RedHill Biopharma sells Talicia stake to Apotex for $18 million upfront, up to $35 million milestones
RDHL•Proceeds to support strategic shift
Proceeds are earmarked to fund a strategic shift toward larger commercial product opportunities and support an accelerated path to operational profitability.
Talicia stake sold for upfront cash and milestones
RedHill Biopharma divested its Talicia business to an Apotex subsidiary for $18 million cash upfront.
The deal includes up to $35 million in potential payments tied to worldwide net sales milestones.
Apotex will acquire RedHill’s 70% interest in Talicia, consolidating ownership following its prior purchase of Cumberland’s 30% stake.
